{"name":"AbCellera Biologics Inc.","slug":"abcellera-biologics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":75128000,"revenueGrowth":160.6,"grossMargin":0,"rdSpend":186829000,"netIncome":-146412000,"cash":1356950000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ABCL575","genericName":"ABCL575","slug":"abcl575","indication":"Other","status":"phase_1"},{"name":"ABCL635","genericName":"ABCL635","slug":"abcl635","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ABCL575","genericName":"ABCL575","slug":"abcl575","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ABCL635","genericName":"ABCL635","slug":"abcl635","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNVVZUdV9vM2tyVHp2S28ybkFVcTBmdjZIOHJSX01oeHNYQjdnenJMSzVhSGNkT3dmbnE3dGZLTXc5anRRMnhSaWN5bGJqYVV1akxGdlQ2VU9DS090d3ZSbU1ucllqRVhpNHFQVW9TbFVkdGpJeGpDY28xdEVfRFNLTWVmM281VzRuRUE?oc=5","date":"2026-02-24","type":"earnings","source":"Yahoo Finance","summary":"AbCellera Biologics Q4 Earnings Call Highlights - Yahoo Finance","headline":"AbCellera Biologics Q4 Earnings Call Highlights","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPaHVzQWxIRTYzbmhldnQ5Wk5VWElwbHFGTUp1WDE0UjRVY2M1UjRnV2lBSWJnRXF4V2tvR1FFZlNXOWhVMnRXZmRORHlkaHN1NE1nMU1EVnBqZ0x0T08tb2pTNmRlVDNIa2ZneVFsSzVJQWt1SVp1cTkyRTF5dDhXeXJtcEFhSUhIZWFTdXdDd2ZOOXQ3?oc=5","date":"2026-02-15","type":"pipeline","source":"The Motley Fool","summary":"Forget AI Stocks: This Pharma Giant Is Using AI to Dominate Drug Discovery - The Motley Fool","headline":"Forget AI Stocks: This Pharma Giant Is Using AI to Dominate Drug Discovery","sentiment":"neutral"},{"date":"2026-01-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPRnMyamlQM3NNX3p1X2Q4YVNvT0g4UENnTEpiMGp2MTZMV191dm1YR3VhWTZUWHVwY2VmbjFSQ3djQURQRE5HallQODd0NzNiY2VqcExza3NwenJETklEeTZFTHFhbENad1JNMkNXLUZEVk12T1g5bngyOHFtTThzZkcxZjBtUGR0V1hIQ3NlcmpXSEJ2Mjc4bllMMFk5Tk1qSUNKWHVIdG4?oc=5","date":"2025-12-11","type":"pipeline","source":"Business in Vancouver","summary":"Could Zymeworks' blockbuster drug success revive Vancouver biotech scene? - Business in Vancouver","headline":"Could Zymeworks' blockbuster drug success revive Vancouver biotech scene?","sentiment":"neutral"},{"date":"2025-11-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxONmxvUmVpc3RXRTNOdGlWRUNUdmRzclFjOURHQnJiY2JtYUliaEFsamVuWDNEMk5FaUhvVjQtTjNsam1WUnE2Q25yQ0RWUy1mYkFnM1N0b1B5d1hUOGZMRXF6T25RMDlRWU5yaWg1enAzYzREVjdHRTdINlhYdmlzWVhvZ1cxSEJnUXk4Zng2SzVqWW9qc1U4Tm5UY1dJSVBWbWNGdkZpVmhGZw?oc=5","date":"2025-11-24","type":"pipeline","source":"The Globe and Mail","summary":"Zymeworks wanted to be Canada’s first Big Pharma. Despite two blockbusters-in-the-making, that’s no longer the plan - The Globe and Mail","headline":"Zymeworks wanted to be Canada’s first Big Pharma. Despite two blockbusters-in-the-making, that’s no longer the plan","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQS1I3T2lpdUFSV282Z0p5aUh5TkZlN0VhWGpIaWEyLV91ZUg1d3ljUk9vVDh0Z2FRUkJnNk9OSU5GaGVjSDE4ajVfbHREbEtjRjVSODFWXy14ZlZPbDFiM0g4V0oteUhvb2h1YUFNQm5PZlpKeE9tUnl6T2p4VzFmZzRoMkwtel9fOEJSZExVRnNBajdSeGlDQnlITWFkbUZ3bWR2Y2dodFdXOVl0UDRvNWhLNWtiRHBRUGpB?oc=5","date":"2025-11-10","type":"pipeline","source":"Business Wire","summary":"AbCellera Appoints Dr. Stephen Quake to its Board of Directors - Business Wire","headline":"AbCellera Appoints Dr. Stephen Quake to its Board of Directors","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE5Sdlp3NmtyazF6Z0Z3bnNfOHRHUktQTk9sY1FlRjZjSnhlVHNJSF85WVBoT00wNkpad3BpRGpMT1ZRWkdycUZhOUxIaVNoWl9tcFpITTUxcXlQVTk2OTFybHZPU3ZLbW0yZC1F?oc=5","date":"2025-08-22","type":"pipeline","source":"MLQ.ai","summary":"Company Overview: A Platform Built for Scale - MLQ.ai","headline":"Company Overview: A Platform Built for Scale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9HNDJKS19wRVBqT3JrX1AyaGpic1plNlB6WERfRlZTUzdqbmNzZE1IWHY4Q0xHNEoteEhGZm4ydmFtZXZwZnNpYWx3Y2kwWnNCVzAtOVJwWkFZX2ti?oc=5","date":"2025-07-18","type":"pipeline","source":"Finimize","summary":"AbCellera’s Platform Pitch Is Winning Investors, But The Numbers Lag - Finimize","headline":"AbCellera’s Platform Pitch Is Winning Investors, But The Numbers Lag","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":75128000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":75128000,"period":"2025-12-31"},{"value":28833000,"period":"2024-12-31"},{"value":28833000,"period":"2024-12-31"},{"value":38025000,"period":"2023-12-31"},{"value":38025000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":186829000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-146412000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1356950000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}